Wellgistics Health has filed an S-1 registration statement with the SEC detailing a plan to integrate XRP and the XRP Ledger (XRPL) across its payments and treasury operations. The health-tech company said it will use XRPL to process real-time, low-cost business-to-business payments among pharmacies, manufacturers, and vendors and expand its XRP holdings. The company may raise capital through equity and debt offerings to purchase additional XRP, deploy those holdings to generate income, and use the asset as collateral for future financing. The S-1 positions XRP as an active balance sheet instrument. Wellgistics intends to accumulate XRP and apply it to several functions: as a payments rail, as collateral to secure financing, and as a source of income generation. The company indicated that treating XRP as collateral could provide liquidity without disrupting operations. It also outlined plans to raise capital specifically for digital asset acquisition, signaling that future issuances of equity or debt may be tied to enlarging its XRP position. Wellgistics will implement XRPL to support near-instant settlement and reduced fees for business partners. The company identified a network of approximately 6,000 pharmacies and 150 manufacturers that will interface with the XRPL-based system. The stated objective is to streamline value transfer and improve liquidity across that ecosystem by avoiding the delays and costs present in traditional payment systems. Beyond the LDA arrangement, the S-1 states that Wellgistics may pursue additional equity and debt offerings to finance XRP purchases and related infrastructure. Additionally, the S-1 includes risk disclosures tied to XRP’s regulatory status and ongoing litigation. Wellgistics warned that adverse legal or regulatory outcomes could affect XRP’s price and, as a result, the value of the company’s treasury assets and collateral.